Amanda Paulovich

Last updated
Amanda Paulovich
Alma mater Carnegie Mellon University
University of Washington
AwardsHUPO Distinguished Achievement in Proteomic Sciences Award (2015)
Scientific career
FieldsBiology
Institutions Fred Hutchinson Cancer Research Center
Thesis The Regulation of S Phase Progression Rate in Yeast in Response to DNA Damage (1996)
Doctoral advisor Leland H. Hartwell

Amanda Grace Paulovich is an oncologist, and a pioneer in proteomics using multiple reaction monitoring mass spectrometry to study tailored cancer treatment.

Contents

Education

Paulovich received a BS in Biological Sciences from Carnegie Mellon University in 1988, [1] a PhD in Genetics from University of Washington in 1996, under the direction of Leland Hartwell. [2] She also received a MD from University of Washington in 1998. [3] Follow her residency in Internal Medicine at Massachusetts General Hospital, she also completed a Postdoctoral Fellowship in Computational Biology at the Massachusetts Institute of Technology Whitehead Center for Genomic Research in 2003, and a Fellowship in Medical Oncology at the Dana Farber Cancer Institute in 2004. [1] [4]

Career

Paulovich is a Professor in Clinical Research, an Aven Foundation Endowed Chair, and the Director of Early Detection Initiative at the Fred Hutchinson Cancer Research Center. [5] [6] She was inducted to the American Society for Clinical Inviestigation in 2012. [7]

Paulovich is an expert in proteomics. [8] Her targeted proteomics method uses multiple reaction monitoring mass spectrometry to target cancer biomarkers with ongoing clinical trials, [9] and was named Method of the Year in 2012 by Nature Methods. [10] [11] She founded Precision Assays in 2016, [12] whose rights to targeted assays were acquired by CellCarta in 2022. [13] [14]

Awards

Patent applications

Related Research Articles

<span class="mw-page-title-main">Proteomics</span> Large-scale study of proteins

Proteomics is the large-scale study of proteins. Proteins are vital parts of living organisms, with many functions such as the formation of structural fibers of muscle tissue, enzymatic digestion of food, or synthesis and replication of DNA. In addition, other kinds of proteins include antibodies that protect an organism from infection, and hormones that send important signals throughout the body.

<span class="mw-page-title-main">Western blot</span> Analytical technique used in molecular biology

The western blot, or western blotting, is a widely used analytical technique in molecular biology and immunogenetics to detect specific proteins in a sample of tissue homogenate or extract. Besides detecting the proteins, this technique is also utilized to visualize, distinguish, and quantify the different proteins in a complicated protein combination.

<span class="mw-page-title-main">Personalized medicine</span> Medical model that tailors medical practices to the individual patient

Personalized medicine, also referred to as precision medicine, is a medical model that separates people into different groups—with medical decisions, practices, interventions and/or products being tailored to the individual patient based on their predicted response or risk of disease. The terms personalized medicine, precision medicine, stratified medicine and P4 medicine are used interchangeably to describe this concept though some authors and organisations use these expressions separately to indicate particular nuances.

Biomarker discovery is a medical term describing the process by which biomarkers are discovered. Many commonly used blood tests in medicine are biomarkers. There is interest in biomarker discovery on the part of the pharmaceutical industry; blood-test or other biomarkers could serve as intermediate markers of disease in clinical trials, and as possible drug targets.

In medicine, a biomarker is a measurable indicator of the severity or presence of some disease state. It may be defined as a "cellular, biochemical or molecular alteration in cells, tissues or fluids that can be measured and evaluated to indicate normal biological processes, pathogenic processes, or pharmacological responses to a therapeutic intervention." More generally a biomarker is anything that can be used as an indicator of a particular disease state or some other physiological state of an organism. According to the WHO, the indicator may be chemical, physical, or biological in nature - and the measurement may be functional, physiological, biochemical, cellular, or molecular.

Digital polymerase chain reaction is a biotechnological refinement of conventional polymerase chain reaction methods that can be used to directly quantify and clonally amplify nucleic acids strands including DNA, cDNA, or RNA. The key difference between dPCR and traditional PCR lies in the method of measuring nucleic acids amounts, with the former being a more precise method than PCR, though also more prone to error in the hands of inexperienced users. A "digital" measurement quantitatively and discretely measures a certain variable, whereas an “analog” measurement extrapolates certain measurements based on measured patterns. PCR carries out one reaction per single sample. dPCR also carries out a single reaction within a sample, however the sample is separated into a large number of partitions and the reaction is carried out in each partition individually. This separation allows a more reliable collection and sensitive measurement of nucleic acid amounts. The method has been demonstrated as useful for studying variations in gene sequences — such as copy number variants and point mutations — and it is routinely used for clonal amplification of samples for next-generation sequencing.

The Early Detection Research Network (EDRN) is a collaboration led by the National Cancer Institute (NCI) focused on the discovery of cancer biomarkers. The effort, started in 2000, includes both principal investigators and associate members from leading research institutions across the United States.

A liquid biopsy, also known as fluid biopsy or fluid phase biopsy, is the sampling and analysis of non-solid biological tissue, primarily blood. Like traditional biopsy, this type of technique is mainly used as a diagnostic and monitoring tool for diseases such as cancer, with the added benefit of being largely non-invasive. Liquid biopsies may also be used to validate the efficiency of a cancer treatment drug by taking multiple samples in the span of a few weeks. The technology may also prove beneficial for patients after treatment to monitor relapse.

<span class="mw-page-title-main">Standard BioTools</span>

Standard BioTools Inc., previously known as Fluidigm Corp., provides an established portfolio of essential, standardized technologies that empower customers to scale and accelerate their life sciences research.

Zeng Rong is a Chinese biochemist researching and developing technology for proteomics research. She is currently a professor at the Institute of Biochemistry and Cell Biology at the Shanghai Institutes for Biological Sciences.

Circulating free DNA (cfDNA) (also known as cell-free DNA) are degraded DNA fragments released to body fluids such as blood plasma, urine, cerebrospinal fluid, etc. Typical sizes of cfDNA fragments reflect chromatosome particles (~165bp), as well as multiples of nucleosomes, which protect DNA from digestion by apoptotic nucleases. The term cfDNA can be used to describe various forms of DNA freely circulating in body fluids, including circulating tumor DNA (ctDNA), cell-free mitochondrial DNA (ccf mtDNA), cell-free fetal DNA (cffDNA) and donor-derived cell-free DNA (dd-cfDNA). Elevated levels of cfDNA are observed in cancer, especially in advanced disease. There is evidence that cfDNA becomes increasingly frequent in circulation with the onset of age. cfDNA has been shown to be a useful biomarker for a multitude of ailments other than cancer and fetal medicine. This includes but is not limited to trauma, sepsis, aseptic inflammation, myocardial infarction, stroke, transplantation, diabetes, and sickle cell disease. cfDNA is mostly a double-stranded extracellular molecule of DNA, consisting of small fragments (50 to 200 bp) and larger fragments (21 kb) and has been recognized as an accurate marker for the diagnosis of prostate cancer and breast cancer.

Stable isotope standards and capture by anti-peptide antibodies (SISCAPA) is a mass spectrometry method for measuring the amount of a protein in a biological sample.

Ying Ge is a Chinese-American chemist who is a Professor of Cell and Regenerative Biology at the University of Wisconsin–Madison. Her research considers the molecular mechanisms that underpin cardiac disease. She has previously served on the board of directors of the American Society for Mass Spectrometry. In 2020 Ge was named on the Analytical Scientist Power List.

Catherine E. Costello is the William Fairfield Warren distinguished professor in the department of biochemistry, Cell Biology and Genomics, and the director of the Center for Biomedical Mass Spectrometry at the Boston University School of Medicine.

Jennifer Eileen Van Eyk is the Erika Glazer Chair in Women's Heart Health, the Director of Advanced Clinical Biosystems Institute in the Department of Biomedical Sciences, the Director of Basic Science Research in the Women's Heart Center, a Professor in Medicine and in Biomedical Sciences at Cedars-Sinai. She is a renowned scientist in the field of clinical proteomics.

Precision diagnostics is a branch of precision medicine that involves precisely managing a patient's healthcare model and diagnosing specific diseases based on customized omics data analytics.

Karin Dorinda Norlin Rodland is an American cancer cell biologist. She is a professor emeritus at Oregon Health and Science University.

The proximity extension assay (PEA) is a method for detecting and quantifying the amount of many specific proteins present in a biological sample such a serum or plasma. The method is used in the research field of proteomics, specifically affinity proteomics, where in one searches for differences in the abundance of many specific proteins in blood for use as a biomarker. Biomarkers and biomarker signature combinations, are useful for determining disease states and drug efficacy. Most methods for detecting proteins involve the use of a solid phase for first capturing and immobilizing the protein analyte, where in one or a few proteins are quantified, such as ELISA. In contrast, PEA is performed without a solid phase in a homogeneous one tube reaction solution where in sets of antibodies coupled to unique DNA sequence tags, so called proximity probes, work in pairs specific for each target protein. PEA is often performed using antibodies and is a type of immunoassay. Target binding by the proximity probes increases their local relative effective concentration of the DNA-tags enabling hybridization of weak complementarity to each other which then enables a DNA polymerase mediated extension forming a united DNA sequence specific for each target protein detected. The use of 3'exonuclease proficient polymerases lowers background noise and hyper thermostable polymerases mediate a simple assay with a natural hot-start reaction. This created pool of extension products of DNA sequence forms amplicons amplified by PCR where each amplicon sequence corresponds to a target proteins identity and the amount reflects its quantity. Subsequently, these amplicons are detected and quantified by either real-time PCR or next generation DNA sequencing by DNA-tag counting. PEA enables the detection of many proteins simultaneously due to the readout requiring the combination of two correctly bound antibodies per protein to generate a detectable DNA sequence from the extension reaction. Only cognate pairs of sequence are detected as true signal, enabling multiplexing beyond solid phase capture methods limited at around 30 proteins at a time. The DNA amplification power also enable minute sample volumes even below one microliter. PEA has been used in over 1000 research publications.

<span class="mw-page-title-main">Olga Ornatsky</span> Canadian Scientist

Olga Ornatsky is a Soviet born, Canadian scientist. Ornatsky co-founded DVS Sciences in 2004 along with Dmitry Bandura, Vladimir Baranov and Scott D. Tanner.

References

  1. 1 2 "Amanda Paulovich, M.D., Ph.D." Fred Hutch. Retrieved 2022-06-06.
  2. ↑ "UW Genome Sciences: Alumni". www.gs.washington.edu. Retrieved 2022-06-06.
  3. ↑ "Alumni Directory | Medical Scientist Training Program" . Retrieved 2022-06-06.
  4. ↑ "Doctors Dr. Amanda G. Paulovich MD". U.S. News & World Report. Retrieved June 6, 2022.
  5. ↑ "MCS Alumna Develops New Technologies for Early Cancer Detection". Carnegie Mellon University Carnegie Mellon Today Archives. September 1, 2004. Retrieved June 6, 2022.
  6. ↑ Pittsburgh, A. Carnegie Mellon University Publication 5000 Forbes Avenue; Pa 15213268-2000. "MCS Alumna Develops New Technologies for Early Cancer Detection". Carnegie Mellon Today. Retrieved 2022-06-06.{{cite web}}: CS1 maint: numeric names: authors list (link)
  7. ↑ "The American Society for Clinical Investigation" . Retrieved 2022-06-08.
  8. ↑ "Interviewer List | Biocompare: The Buyer's Guide for Life Scientists". www.biocompare.com. Retrieved 2022-06-08.
  9. ↑ "CPTAC Contributes to the Identification of a Novel Pharmacodynamic Biomarker for Clinical Trial Use | Office of Cancer Clinical Proteomics Research". proteomics.cancer.gov. Retrieved 2022-06-08.
  10. ↑ "Beyond genomics: Using proteomics to target tumors". ScienceDaily. Retrieved 2022-06-08.
  11. ↑ "Fred Hutch's Paulovich lab to lead protein assay work for Beau Biden Cancer Moonshot". American Association for the Advancement of Science (AAAS) EurekAlert! Archive. 2017-02-06. Retrieved 2022-06-08.
  12. ↑ "PRECISION ASSAYS, LLC :: Washington (US) :: OpenCorporates". opencorporates.com. Retrieved 2022-06-08.
  13. ↑ "CellCarta Acquires Next-Generation Immuno-MRM Assays from Precision Assays". CellCarta. Retrieved 2022-06-08.
  14. ↑ CellCarta. "CellCarta expands it proteomics portfolio with the acquisition of next-generation immuno-MRM assays from Precision Assays". www.newswire.ca. Retrieved 2022-06-08.
  15. ↑ "Pappu recognized as 'woman to watch' in life science". WSU Insider. Retrieved 2022-06-06.
  16. ↑ "MSACL-Paulovich". www.msacl.org. Retrieved 2022-06-06.
  17. ↑ "HUPO - Past Award Recipients". www.hupo.org. Retrieved 2022-06-06.
  18. ↑ "SCIEX Partners with the Paulovich Lab at Fred Hutchinson Cancer Research Center to Advance Cancer Research Reproducibility". www.businesswire.com. 2015-09-22. Retrieved 2022-06-06.
  19. ↑ USapplication 20130052668A1 Amanda G. Paulovich, Richard G. Ivey/Fred Hutchinson Cancer Research Center: "Identification and use of biomarkers for detection and quantification of the level of radiation exposure in a biological sample" filing date 29.04.2011
  20. ↑ USapplication 20130052669A1 Amanda G. Paulovich, Richard G. Ivey/Fred Hutchinson Cancer Research Center: "Compositions and methods for reliably detecting and/or measuring the amount of a modified target protein in a sample" filing date 29.04.2011
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.